Aqemia co-founders Emmanuelle Martiano Rolland (left) and Maximilien Levesque

Sanofi forms drug dis­cov­ery pact with French start­up Aqemia en route to ‘AI at scale’ am­bi­tion

Sanofi CEO Paul Hud­son has been clear about his com­pa­ny’s bets on drug dis­cov­ery’s hottest tech­nol­o­gy — tout­ing plans to be the “first phar­ma com­pa­ny pow­ered by ar­ti­fi­cial in­tel­li­gence at scale” — and it has now lined up an­oth­er pact to get there.

The French phar­ma gi­ant will pay up to $140 mil­lion to Paris-based Aqemia as part of a mul­ti-year col­lab­o­ra­tion to cre­ate small mol­e­cules for more than one ther­a­peu­tic area. Fur­ther de­tails on the up­front break­down, time­line and spe­cif­ic dis­ease ar­eas were kept un­der wraps.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.